Published in Bone Marrow Transplant on February 01, 2004
Reconstitution of the immune system after hematopoietic stem cell transplantation in humans. Semin Immunopathol (2008) 1.42
Epidemiology and treatment approaches in management of invasive fungal infections. Clin Epidemiol (2011) 1.20
Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis (2012) 1.03
Response to pneumococcal (PNCRM7) and haemophilus influenzae conjugate vaccines (HIB) in pediatric and adult recipients of an allogeneic hematopoietic cell transplantation (alloHCT). Biol Blood Marrow Transplant (2008) 0.88
Interleukin 12 (IL-12) family cytokines: Role in immune pathogenesis and treatment of CNS autoimmune disease. Cytokine (2015) 0.88
NCI, NHLBI/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: persistent immune deficiency in pediatric transplant survivors. Biol Blood Marrow Transplant (2011) 0.85
Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients. Bone Marrow Transplant (2012) 0.84
Resetting the adaptive immune system after autologous stem cell transplantation: lessons from responses to vaccines. J Clin Immunol (2007) 0.83
Pretransplant vaccinations in allogeneic stem cell transplantation donors and recipients: an often-missed opportunity for immunoprotection? Bone Marrow Transplant (2015) 0.81
Post-transplant adoptive T-cell immunotherapy. Best Pract Res Clin Haematol (2008) 0.81
B cells and transplantation: an educational resource. Biol Blood Marrow Transplant (2009) 0.80
Trypanosoma-Cruzi Cross-Reactive Antibodies Longitudinal Follow-Up: A Prospective Observational Study in Hematopoietic Stem Cell Transplantation. PLoS One (2015) 0.75
Control of hepatitis B virus infection in hematopoietic stem cell recipients after receiving grafts from vaccinated donors. Bone Marrow Transplant (2015) 0.75
Vaccination of hematopoietic stem cell transplantation recipients: perspective in Korea. Infect Chemother (2013) 0.75
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood (2001) 4.65
Solid cancers after bone marrow transplantation. N Engl J Med (1997) 4.62
Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med (1982) 3.78
Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet (2000) 3.22
Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood (1981) 3.03
Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood (1999) 2.97
Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med (1990) 2.66
Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood (1999) 2.65
Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol (2000) 2.38
A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood (2000) 2.11
Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood (2001) 2.04
Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood (2001) 1.92
New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol (2000) 1.92
Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia (2006) 1.92
A clinical trial of anti-idiotype therapy for B cell malignancy. Blood (1985) 1.91
Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med (1983) 1.89
Cytomegalovirus (CMV) DNA load in plasma for the diagnosis of CMV disease before engraftment in hematopoietic stem-cell transplant recipients. J Infect Dis (2000) 1.87
A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant (2006) 1.84
Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood (1985) 1.81
High-level sensitivity of quantitative pp65 cytomegalovirus (CMV) antigenemia assay for diagnosis of CMV disease in AIDS patients and follow-up. J Clin Microbiol (1996) 1.81
Factors influencing detection of quantitative cytomegalovirus antigenemia. J Clin Microbiol (1994) 1.81
Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood (1997) 1.80
Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood (1996) 1.77
Ovarian function following marrow transplantation for aplastic anemia or leukemia. J Clin Oncol (1988) 1.72
Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. Blood (1999) 1.72
Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood (1997) 1.64
Comparison of conventional and molecular detection of respiratory viruses in hematopoietic cell transplant recipients. Transpl Infect Dis (2009) 1.64
Long-term outcome after marrow transplantation for severe aplastic anemia. Blood (1998) 1.63
Nontuberculous mycobacterial infections in hematopoietic stem cell transplant recipients: characteristics of respiratory and catheter-related infections. Biol Blood Marrow Transplant (2000) 1.57
Association of specific cytomegalovirus genotypes with death from myelosuppression after marrow transplantation. Blood (1997) 1.57
In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia. Blood (1981) 1.52
Recent advances in the therapy and prevention of CMV infections. J Clin Virol (2000) 1.51
Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med (1983) 1.44
Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience. Biol Blood Marrow Transplant (2001) 1.44
Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: characterization and use as probes for the biology of the tumor in vivo and in vitro. Hybridoma (1985) 1.43
Hepatic mucormycosis in a bone marrow transplant recipient who ingested naturopathic medicine. Clin Infect Dis (1996) 1.43
Cytomegalovirus infection and ganciclovir resistance caused by UL97 mutations in pediatric transplant recipients. Transpl Infect Dis (2012) 1.42
Bile secretory apparatus: evidence for a vesicular transport mechanism for proteins in the rat, using horseradish peroxidase and [125I]insulin. Gastroenterology (1980) 1.42
Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants. J Immunol (1986) 1.40
Infant Airtraq for adult bougie placement. Anaesthesia (2014) 1.39
Rhinovirus as a cause of fatal lower respiratory tract infection in adult stem cell transplantation patients: a report of two cases. Bone Marrow Transplant (2007) 1.37
Bayesian estimation of hepatitis E virus seroprevalence for populations with different exposure levels to swine in The Netherlands. Epidemiol Infect (2007) 1.34
T cell reconstitution after bone marrow transplantation into adult patients does not resemble T cell development in early life. Bone Marrow Transplant (1995) 1.31
Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. J Immunol (1987) 1.28
Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Blood (1996) 1.27
Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts. Am J Hematol (1997) 1.27
Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant (1988) 1.27
Marrow harvesting from normal donors. Blood (1984) 1.25
Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation. Blood (2001) 1.24
Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood (1988) 1.23
Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood (1997) 1.23
Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood (2000) 1.22
Frequency distribution of cytomegalovirus envelope glycoprotein genotypes in bone marrow transplant recipients. J Infect Dis (1994) 1.21
Analysis of late infections in 89 long-term survivors of bone marrow transplantation. Blood (1979) 1.21
Growth and development following marrow transplantation for leukemia. Blood (1986) 1.20
Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation. Clin Infect Dis (2001) 1.18
Previous donor pregnancy as a risk factor for acute graft-versus-host disease in patients with aplastic anaemia treated by allogeneic marrow transplantation. Br J Haematol (1990) 1.17
Hepatitis E is a cause of unexplained hepatitis in The Netherlands. J Clin Virol (2004) 1.17
Anemia in hypothyroidism. South Med J (1970) 1.16
Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol (1999) 1.14
Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood (1998) 1.14
Failure of rituximab monotherapy in lymphomatoid granulomatosis. Eur J Haematol (2005) 1.14
Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol (1998) 1.13
Evaluation of CMV Brite kit for detection of cytomegalovirus pp65 antigenemia in peripheral blood leukocytes by immunofluorescence. J Clin Microbiol (1996) 1.12
Immunologic reconstitution after human marrow grafting. Semin Hematol (1984) 1.10
Idiopathic pneumonia syndrome: changing spectrum of lung injury after marrow transplantation. Transplantation (1997) 1.10
Late effects on gonadal function of cyclophosphamide, total-body irradiation, and marrow transplantation. Transplantation (1983) 1.10
Cytomegalovirus disease occurring before engraftment in marrow transplant recipients. Clin Infect Dis (1997) 1.08
Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin. Blood (1997) 1.08
Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial. Blood (2001) 1.08
Decreased incidence of marrow graft rejection in patients with severe aplastic anemia: changing impact of risk factors. Blood (1986) 1.07
Strategies for production of monoclonal anti-idiotype antibodies against human B cell lymphomas. J Immunol (1984) 1.06
Factors influencing B lymphopoiesis after allogeneic hematopoietic cell transplantation. Blood (2001) 1.03
Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation. Bone Marrow Transplant (2007) 1.03
Marrow transplantation for paroxysmal nocturnal hemoglobinuria. Am J Hematol (1992) 1.03
Allogeneic peripheral blood stem cell graft composition affects early T-cell chimaerism and later clinical outcomes after non-myeloablative conditioning. Br J Haematol (2005) 1.02
DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient. Transpl Infect Dis (2012) 1.02
Invasive Pseudomonas aeruginosa infections: high rate of recurrence and mortality after hematopoietic cell transplantation. Bone Marrow Transplant (2007) 1.01
Treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Randomized study comparing corticosteroids and cyclosporine. Am J Med (1985) 1.00
Low-dose cyclophosphamide conditioning for haematopoietic cell transplantation from HLA-matched related donors in patients with Fanconi anaemia. Br J Haematol (2005) 1.00
Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematology Am Soc Hematol Educ Program (2001) 1.00
Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med (1989) 1.00